Scott Tetreault, MD
Basic profileFlorida Cancer Specialists & Research Institute
Scott Tetreault is an Oncology physician affiliated with Florida Cancer Specialists & Research Institute. OpenAlex indexes 7 publications with 341 citations (h-index 4).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1815 Tuscan Hill Dr
Tallahassee, FL 323124287
Telephone
941-916-3399Provider last certified this registry record 28 May 2026.
Industry payments
77 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20257 payments
- E.R. Squibb & Sons, L.L.C.Program year20256 payments
- Celgene CorporationProgram year20255 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
78.5%Erythropoiesis-stimulating Agent68.1%Epoetin alfa100%Part B, office-administered≥18 patientsIron, parenteral preparations10.1%Ferric derisomaltose100%Part B, office-administered≥14 patients+ 1 more class in this area
Sensory organs
12.1%Corticosteroid12.1%Dexamethasone sodium phosphate100%Dexamethasone1%Part D + Part B≥39 patientsMetabolism & gastrointestinal
3.9%Serotonin-3 Receptor Antagonist3.5%Ondansetron hydrochloride94%Ondansetron Odt4%Ondansetron Hcl3%Part D + Part B≥16 patientsCorticosteroid0.3%Prednisone100%Part D≥24 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma
Journal of Clinical Oncology
2019 - DYNAMO: A phase 2 trial of the PI3K-δ,γ inhibitor IPI-145 in patients with refractory indolent non-Hodgkin lymphoma.
Journal of Clinical Oncology
2014 - 'Economies of scale' yield multiple benefits for a private, physician-run oncology practice.
PubMed
2013
Similar KOLs
Other experts from the same institution or the same specialty.
Bradley Monk, MD
Florida Cancer Specialists & Research Institute
Satish Shanbhag, MD, MPH
Florida Cancer Specialists & Research Institute
Ivor Percent, MD
Florida Cancer Specialists & Research Institute
Bradford Perez, MD
Florida Cancer Specialists & Research Institute
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”